Peters S, et al. Nivolumab + low-dose ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non–small cell lung cancer: CheckMate-227 part 1 final analysis. ESMO Congress 2019, abstract LBA4.
Adjuvant ipilimumab bij stadium III-melanoom
jan 2017 | Dermato-oncologie, Immuuntherapie